Litigation Details for ALEMBIC PHARMACEUTICALS, LTD v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)
✉ Email this page to a colleague
ALEMBIC PHARMACEUTICALS, LTD v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)
Docket | ⤷ Sign Up | Date Filed | 2019-11-27 |
Court | District Court, D. New Jersey | Date Terminated | 2020-01-29 |
Cause | 28:1338 Patent Infringement | Assigned To | Stanley R. Chesler |
Jury Demand | None | Referred To | Cathy L. Waldor |
Patents | 6,465,504; 9,283,209 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in ALEMBIC PHARMACEUTICALS, LTD v. NOVARTIS PHARMACEUTICALS CORP.
Details for ALEMBIC PHARMACEUTICALS, LTD v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2019-11-26 | 1 | , two patents were listed in FDA’s Orange Book as covering Jadenu®: U.S. Patent No. 6,465,504 (“the …resolution of patent disputes by authorizing a patent owner to sue an ANDA applicant for patent infringement…’209 Patent. 100. The ’209 Patent discloses Opadry coating material. See ’209 Patent, col.…Page 2 of 122 PageID: 2 Patent”). Alembic brings this suit to obtain patent certainty under 21 U.S.C.… obtain patent certainty” when a generic applicant makes such certifications, and the patent owner does | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |